Rachelle Suzanne Jacques Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Rachelle Suzanne Jacques sold 1,993 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the transaction, the director directly owned 33,903 shares of the company’s stock, valued at $917,415.18. This trade represents a 5.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

uniQure Trading Up 2.8%

Shares of QURE stock traded up $0.75 on Friday, hitting $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The firm has a market cap of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a fifty day moving average price of $22.31 and a two-hundred day moving average price of $21.76. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in uniQure during the 3rd quarter worth about $50,000. Torren Management LLC bought a new stake in uniQure during the 4th quarter worth about $28,000. FNY Investment Advisers LLC lifted its position in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares in the last quarter. Finally, IFP Advisors Inc bought a new stake in uniQure during the 4th quarter worth about $48,000. 78.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. The Goldman Sachs Group boosted their price objective on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Wolfe Research assumed coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.